J. Casal

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

Mariano Provencio-Pulla, Ernest Nadal-Alforja, Manuel Cobo et al. · Journal of Clinical Oncology · 2018 · 68 citations

Surgical Oncology, Medicine, High Response Rate +12

Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.

Mariano Provencio-Pulla, Ernest Nadal, J.L. González-Larriba et al. · Journal of Clinical Oncology · 2022 · 61 citations

Surgical Oncology, Oncology, Pcr Rate +13

Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · The Lancet Oncology · 2024 · 51 citations · Full text

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +8

The LNK Gene Family: At the Crossroad between Light Signaling and the Circadian Clock

María José de Leone, Carlos Esteban Hernando, Andrés Romanowski et al. · Genes · 2018 · 36 citations · Full text

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

Serafín Morales, Antonio Lorenzo, Manuel Ramos et al. · Cancer Chemotherapy and Pharmacology · 2003 · 23 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +7